We are pleased to announce that last week we received notification from FINRA that our application for membership has been approved. Approval of the application, the culmination of a nearly ten-month process, formally designates the firm as a registered broker/dealer allowing us to participate in regulated securities transactions. FINRA membership extends the services we are able to provide earlier-stage life science companies to include private equity placements and transaction advisory services, including licensing, strategic partnerships and alliances, and mergers & acquisitions engagements, where we participate on both buy-side and sell-side engagements. These capabilities build upon decades of prior investment banking, strategy consulting and corporate management experience.
Differentiating our transaction business are a range of complementary services that are offered in conjunction with Danforth Advisors and tailored primarily to the needs of emerging stage biopharmaceutical companies, including a chief medical officer executive network that provides access to distinguished senior-level talent on an interim or fractional basis and our IPO preparation services, where we work closely with company management to draft a compelling and thoughtful business section for S-1, F-1 and certain S-4 filings. We believe the seamless integration of this suite of capabilities addresses needs central to our clients’ success.
BJC Capital Advisors LLC